Shares of Peregrine Pharmaceuticals (NASDAQ: PPHM ) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer, dipped as much as 11% after reporting its third-quarter earnings results. Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was -8.05% in last session and finished the day at $2.40. Traded volume was 14.14million shares in the last session and the average volume of the stock remained 4.31million shares. The beta of the stock remained 1.40. Peregrine Pharmaceuticals (NASDAQ:PPHM) insider ownership is 0.20%.

Merck & Co., Inc. (NYSE:MRK) was the most admired corporation in America — but even at Merck at the time that Boger left, the chemists reported to me, there were benchmarks and goals set; numbers of compounds made, for instance, in a program. It didn’t matter whether they were an improvement over anything else. Merck & Co., Inc. (NYSE:MRK) Rose 0.37 percent to $57.47 Friday on volume of 10.63million shares. The intra-day range of the stock was $57.10 to $57.57. Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $169.00billion.

Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) announces the launch of the generic equivalent to Xeloda® (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda® is marketed by Genentech in the United States. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s stock on Mar 7, 2014 reported a decrease of -1.04% to the closing price of $49.30. Its fifty two weeks range is $36.26-$51.41. The total market capitalization recorded $46.76billion. The overall volume in the last trading session was 10.38million shares. In its share capital, TEVA has 847.00million outstanding shares.

A Lewiston couple sat shame-faced in an Androscoggin County courtroom last week as a judge pronounced them guilty of stealing about $20,000 in housing benefits intended for the poor. Abbott Laboratories (NYSE:ABT), meanwhile, paid Maine $1,607,808 in another settlement the same year. On Friday, shares of Abbott Laboratories (NYSE:ABT) dropped -0.40% to close the day at $39.57. Company return on investment (ROI) is 8.00% and its monthly performance is recorded as 8.86%. Abbott Laboratories (NYSE:ABT) quarterly revenue growth is 6.51%.